Toshifumi Hibi

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 17

Top Topics

Ulcerative Colitis

Top Venues

Nature reviews. Gastroenterology & hepatology

Journal of gastroenterology and hepatology

Journal of gastroenterology

Alimentary pharmacology & therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Taku Kobayashi, Toshifumi Hibi
Author Correction: Improving IBD outcomes in the era of many treatment options. Nature reviews. Gastroenterology & hepatology (2023)
Taku Kobayashi, Toshifumi Hibi
Improving IBD outcomes in the era of many treatment options. Nature reviews. Gastroenterology & hepatology 20 (2) (2023)
Taku Kobayashi, Toshifumi Hibi
Improving IBD outcomes in the era of many treatment options. Nature reviews. Gastroenterology & hepatology 20 (2) (2023)
Katsuyoshi Matsuoka, Toshifumi Hibi
Author Correction: Etrasimod for ulcerative colitis: evaluating phase III results. Nature reviews. Gastroenterology & hepatology (2023)
Taku Kobayashi, Toshifumi Hibi
Improving IBD outcomes in the era of many treatment options. Nature reviews. Gastroenterology & hepatology (2023)
Taku Kobayashi, Toshifumi Hibi
Author Correction: Improving IBD outcomes in the era of many treatment options. Nature reviews. Gastroenterology & hepatology (2023)
Taku Kobayashi, Toshifumi Hibi
Improving IBD outcomes in the era of many treatment options. Nature reviews. Gastroenterology & hepatology 20 (2) (2023)
Taku Kobayashi, Toshifumi Hibi
Improving IBD outcomes in the era of many treatment options. Nature reviews. Gastroenterology & hepatology (2023)
Taku Kobayashi, Toshifumi Hibi
Improving IBD outcomes in the era of many treatment options. Nature reviews. Gastroenterology & hepatology (2023)
Katsuyoshi Matsuoka, Toshifumi Hibi
Etrasimod for ulcerative colitis: evaluating phase III results. Nature reviews. Gastroenterology & hepatology (2023)
Shintaro Sagami, Taku Kobayashi, Kanako Aihara, Misaki Umeda, Kazuhiro Odajima, Hiromu Morikubo, Kunio Asonuma, Yusuke Miyatani, Tomohiro Fukuda, Mao Matsubayashi, Hiroki Kiyohara, Masaru Nakano, Toshifumi Hibi
Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. Alimentary pharmacology & therapeutics 55 (10) (2022)
Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Hyo Jong Kim, Byong Duk Ye, Shoko Arai, Masato Hoshi, Hirotoshi Yuasa, Junichi Tabira, Shigeyuki Toyoizumi, Nanzhi Shi, Joon-Suk Woo, Toshifumi Hibi
Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open. Journal of gastroenterology and hepatology 37 (10) (2022)
Shintaro Sagami, Kiyohiro Nishikawa, Fumika Yamada, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi
Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. Journal of gastroenterology and hepatology 36 (8) (2021)
Katsuyoshi Matsuoka, Hirono Ishikawa, Takeo Nakayama, Yusuke Honzawa, Atsuo Maemoto, Fumihito Hirai, Fumiaki Ueno, Noriko Sato, Yutaka Susuta, Toshifumi Hibi
Physician-patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis. Journal of gastroenterology 56 (9) (2021)
Shintaro Sagami, Taku Kobayashi, Toshifumi Hibi
Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis-one more arrow in the quiver of non-invasive diagnostics. Authors' reply. Alimentary pharmacology & therapeutics 52 (2) (2020)
Satoshi Motoya, Kenji Watanabe, Haruhiko Ogata, Takanori Kanai, Toshiyuki Matsui, Yasuo Suzuki, Mitsuhiro Shikamura, Kenkichi Sugiura, Kazunori Oda, Tetsuharu Hori, Takahiro Araki, Mamoru Watanabe, Toshifumi Hibi
Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PloS one 14 (2) (2019)
Kenji Watanabe, Satoshi Motoya, Haruhiko Ogata, Takanori Kanai, Toshiyuki Matsui, Yasuo Suzuki, Mitsuhiro Shikamura, Kenkichi Sugiura, Kazunori Oda, Tetsuharu Hori, Takahiro Araki, Mamoru Watanabe, Toshifumi Hibi
Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. Journal of gastroenterology 55 (3) (2019)